Holdings
Affinity Asset Advisors, LLC
As of Jun 30, 2026, Affinity Asset Advisors, LLC reported 87 positions worth US$1.87B. Largest: Roivant Sciences Ltd., Apogee Therapeutics, Inc. and Spyre Therapeutics, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 3.75M | US$133M | +950K | Jun 30, 2026 |
| Apogee Therapeutics, Inc. | 987K | US$131M | −298K | Jun 30, 2026 |
| Spyre Therapeutics, Inc. | 1.28M | US$114M | no change | Jun 30, 2026 |
| Xenon Pharmaceuticals Inc. | 1.59M | US$96.3M | −80,000 | Jun 30, 2026 |
| Erasca, Inc. | 5.25M | US$96.2M | −100K | Jun 30, 2026 |
| Insmed Incorporated | 650K | US$69.3M | +170K | Jun 30, 2026 |
| Praxis Precision Medicines, Inc. | 185K | US$61.9M | +15,000 | Jun 30, 2026 |
| Oruka Therapeutics, Inc. | 590K | US$56.2M | +90,327 | Jun 30, 2026 |
| Anaptysbio, Inc. | 826K | US$55.8M | −114K | Jun 30, 2026 |
| Avalo Therapeutics, Inc. | 2.9M | US$53.6M | +1.56M | Jun 30, 2026 |